VE-303 is under clinical development by Vedanta Biosciences and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VE-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VE-303 overview
VE-303 is under development for the treatment of cirrhosis, hepatic encephalopathy, colitis and Clostridium difficile infections. It is administered through oral route and formulated as a capsule. The drug candidate consists of a defined consortia of live bacteria. It acts by modulating pathways of interaction between the human microbiome and the host immune system to treat inflammatory diseases.
See Also:
Vedanta Biosciences overview
Vedanta Biosciences clinical-stage microbiome company that develops oral therapies based on defined bacterial consortia. The company’s product pipeline includes VE303, VE202, VE800, VE707, and VE416. Its products are used in treating clostridioides difficile (CDI) infection, inflammatory bowel disease (IBD), immuno-oncology, carbapenem-resistant Enterobacteriaceae (CRE), vancomycin-resistant Enterococci (VRE), extended-spectrum beta-lactamase producers (ESBL), and food allergy. Vedanta Bioscience’s proprietary discovery and development platform enables the identification of defined bacterial consortia with drug-like properties. Its manufacturing facility enables the production of bacterial consortia and handles multiple drug candidates for clinical studies and commercial launches. The company works in collaboration with Bristol Myers Squibb Inc, Biomedical Advanced Research and Development Agency (BARDA), JSR Corp, Leiden University Medical Center, Vall d’Hebron Institute of Oncology, NYU Langone Medical Center, and others for research and development. Vedanta Biosciences is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of VE-303’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
